AI
Thursday, December 22, 2011 5:04:29 PM
Without knowing more details If I were to speculate I think its a so-so deal. I think it reflects that Biosimilars may be more competitive and a harder sell. We don't know what stage of development and which compounds were selected.
Given that FoB are many years out and its looking more and more competitive I would have preferred bigger up front money
... But then again the royalties are pretty low as it is so not much room to trade down royalties for more upfront.
Given that FoB are many years out and its looking more and more competitive I would have preferred bigger up front money
... But then again the royalties are pretty low as it is so not much room to trade down royalties for more upfront.
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
